Peptides, SARMs, and anabolic steroids are 3 fundamentally different chemical categories that work through 3 different mechanisms — peptides are amino acid signaling molecules that work with the body's natural pathways, SARMs are non-steroidal small molecules that bind androgen receptors selectively, and steroids are synthetic testosterone derivatives that bind androgen receptors non-selectively throughout the body. Calling a peptide a "steroid" or a SARM a "peptide" is not a matter of preference — it is scientifically incorrect and leads to dangerous misunderstandings about how each category affects the body.
This confusion is pervasive. Online vendors list MK-677 under "SARMs" when it is neither a SARM nor a peptide. Reddit threads ask whether BPC-157 is a steroid. Fitness influencers use "peptides" and "SARMs" interchangeably. The result is that users make decisions about compounds they fundamentally misunderstand — choosing based on marketing category rather than mechanism of action, receptor target, or safety profile.
This guide provides a definitive, science-based classification: what each category is, how they work, where commonly misclassified compounds actually belong, and how the three compare on testosterone suppression, safety, legal status, muscle-building potency, and quality verification. For compound-specific information on any peptide, browse Peptigrity's peptide guide pages. For the peptide-specific muscle growth category, see the pillar page.
What Are Peptides, SARMs, and Steroids? 3 Fundamentally Different Categories
Peptides, SARMs, and anabolic steroids are 3 fundamentally different chemical categories — they differ in chemical structure, mechanism of action, receptor targets, and regulatory status. Understanding these definitions is the prerequisite for every comparison that follows.
Peptides are short chains of amino acids — typically 2–50 residues — that act as signaling molecules in the body. They bind to specific receptors and trigger biological responses: growth hormone release (GH secretagogues such as CJC-1295 and Ipamorelin), tissue repair (BPC-157, TB-500), appetite regulation (GLP-1 receptor agonists such as semaglutide and tirzepatide), immune modulation (Thymosin Alpha-1), and neuroprotection (Semax, Selank). Peptides are water-soluble, typically administered by subcutaneous injection or intranasal spray, and work WITH the body's existing signaling pathways rather than overriding them. Over 110 peptides have been approved globally as pharmaceutical drugs. They do not suppress testosterone production.
SARMs (Selective Androgen Receptor Modulators) are synthetic, non-steroidal small molecules that bind directly to androgen receptors in muscle and bone tissue. They are designed to produce anabolic (muscle-building) effects while minimizing androgenic effects on the prostate, liver, skin, and hair. Common examples include Ostarine (MK-2866), Ligandrol (LGD-4033), RAD-140 (Testolone), and Andarine (S-4). SARMs are orally active, based on aryl-propionamide or quinolone chemical scaffolds, and are NOT peptides — they share no structural similarity with amino acid chains. As of 2026, zero SARMs have been approved by the FDA for any indication. They DO suppress testosterone production in most cases. According to NCBI LiverTox, SARMs have been implicated in multiple cases of severe cholestatic jaundice.
Anabolic-androgenic steroids (AAS) are synthetic derivatives of testosterone with a characteristic four-ring cholesterol-derived steroid structure. They bind to androgen receptors non-selectively — affecting muscle, bone, prostate, skin, hair, liver, and the cardiovascular system. Common examples include testosterone, nandrolone (Deca-Durabolin), trenbolone, oxandrolone (Anavar), and stanozolol (Winstrol). Steroids are the most potent muscle-building agents of the three categories but carry the most severe and well-documented side effect profile. Several steroids are FDA-approved for specific medical indications (hypogonadism, HIV-associated muscle wasting, certain anemias). They are classified as Schedule III controlled substances in the United States. They cause strong testosterone suppression and always require post-cycle therapy (PCT).
How Do They Work? Mechanism of Action Compared
The fundamental difference is WHERE in the biological chain each category acts — peptides signal upstream hormonal pathways (telling the pituitary to release GH), SARMs bind directly to androgen receptors in target tissues (telling muscle cells to grow), and steroids flood androgen receptors non-selectively across every tissue in the body.
Peptides work indirectly. GH secretagogues such as CJC-1295 and Ipamorelin stimulate the pituitary gland to release your own endogenous growth hormone, which then elevates IGF-1 (Insulin-like Growth Factor 1) in the liver, which supports protein synthesis, fat metabolism, and cellular repair. Healing peptides such as BPC-157 and TB-500 promote tissue repair through angiogenesis, cell migration, and growth factor modulation. Neither peptide category directly activates androgen receptors. The key distinction: peptides signal the body to produce more of its own hormones within physiological ranges. They amplify existing signaling — they do not introduce exogenous androgenic compounds.
SARMs work directly on androgen receptors in muscle and bone, mimicking testosterone's anabolic signaling in those target tissues. When you take a SARM like Ostarine or RAD-140, it circulates to muscle cells and binds to the androgen receptor, triggering increased protein synthesis and muscle growth. The "selective" aspect refers to the design intention — SARMs are engineered to preferentially activate receptors in muscle and bone while minimizing activity in the prostate, liver, and skin. However, published research demonstrates that this selectivity is relative, not absolute. Narayanan et al. noted that while SARMs show promise in muscle wasting disorders, safety concerns persist due to limited long-term data and incomplete tissue selectivity. Off-target effects still occur.
Steroids work directly and non-selectively. Testosterone and its synthetic derivatives bind to androgen receptors in virtually every tissue — muscle, bone, prostate, skin, hair follicles, sebaceous glands, liver, and cardiovascular tissue. This non-selectivity is what makes steroids both the most effective muscle-building agents and the most systemically dangerous. The muscle growth stimulus is powerful and direct, but so is the prostate stimulation, the liver stress (particularly with oral steroids), the lipid profile disruption, and the suppression of natural hormone production.
This mechanistic difference explains why peptides do not suppress testosterone while SARMs and steroids do. Peptides operate on the GH axis — a completely separate endocrine pathway from the hypothalamic-pituitary-testicular axis (HPTA) that governs testosterone. SARMs and steroids both activate androgen receptors, which triggers negative feedback on the HPTA and suppresses endogenous testosterone production.
Where Does MK-677 (Ibutamoren) Actually Fit?
MK-677 (Ibutamoren) is the single most misclassified compound in the performance space — it is listed as a "SARM" by most research chemical vendors, but it is not a SARM, not a peptide, and not a steroid — it is a non-peptide, orally active ghrelin receptor agonist that stimulates growth hormone release through a mechanism entirely separate from androgen receptor signaling.
The classification confusion exists for one simple reason: MK-677 is sold alongside SARMs by research chemical companies and appears in the "SARM" category of their product catalogs. This is a marketing grouping, not a pharmacological classification. NCBI LiverTox explicitly notes that MK-677, along with compounds like Stenabolic (SR9009) and Cardarine (GW-501516), are "sometimes mistakenly claimed to be SARMs" but are pharmacologically distinct. The US Department of Defense Operation Supplement Safety classifies MK-677 as a "growth hormone secretagogue" — not a SARM.
What MK-677 actually is: a potent, long-acting, orally active, non-peptide agonist of the ghrelin receptor (GHS-R1a). It mimics the endogenous hormone ghrelin to stimulate growth hormone and IGF-1 release from the pituitary gland. Its chemical structure is a synthetic propanamide derivative — it has no amino acid backbone (so it is not a peptide) and no steroid ring structure (so it is not a steroid). It does not bind to androgen receptors (so it is not a SARM).
What MK-677 is closest to: functionally, it belongs with the GH secretagogue peptide class. Its mechanism — stimulating GH release through the ghrelin receptor — is the same pathway used by injectable peptide secretagogues such as Ipamorelin and GHRP-6. The difference is structural: MK-677 is a small molecule with oral bioavailability, while Ipamorelin and GHRP-6 are peptides that require injection. By effect, MK-677 belongs in the GH secretagogue family. By chemical structure, it belongs in the small-molecule drug class.
Why Peptigrity does not cover MK-677: Peptigrity is a peptide review platform. Wikipedia, NCBI LiverTox, and PubChem all classify MK-677 as a non-peptide compound. Including it on a peptide platform would be scientifically inaccurate. MK-677 does not suppress testosterone (no androgen receptor activity), and it does not require PCT.
Do They Suppress Testosterone? The PCT Question Answered
Peptides do not suppress testosterone production — they operate on entirely separate receptor systems — while both SARMs and anabolic steroids suppress the hypothalamic-pituitary-testicular axis (HPTA) and typically require post-cycle therapy (PCT) to restore natural testosterone after discontinuation.
Peptides: NO suppression, NO PCT needed. GH secretagogues (CJC-1295, Ipamorelin, Sermorelin, GHRP-2, GHRP-6) operate on the GH axis — the GHRH receptor and ghrelin receptor on the pituitary gland. This axis is completely separate from the HPTA that controls testosterone production. Healing peptides (BPC-157, TB-500) work through growth factor modulation, nitric oxide signaling, and cell migration pathways that have no interaction with androgen receptors. GLP-1 receptor agonists (semaglutide, tirzepatide) act on metabolic and appetite pathways. None of these peptide categories affect LH (luteinizing hormone), FSH (follicle-stimulating hormone), or testosterone levels.
SARMs: YES — moderate suppression, PCT usually recommended. Despite being designed for "selective" androgen receptor activity, SARMs suppress natural testosterone production. Published research from Bhasin et al. in the Journal of Clinical Endocrinology & Metabolism demonstrated that SARM use causes suppression of LH and reduction of total testosterone in male subjects. The degree of suppression varies by compound and dose — Ostarine produces milder suppression than RAD-140 or LGD-4033 — but the effect is consistent across the class. PCT (typically using Clomid or Nolvadex) is usually recommended after SARM cycles to restore endogenous testosterone production.
Steroids: YES — severe suppression, PCT always required. Exogenous androgens trigger a strong negative feedback loop on the HPTA, effectively shutting down natural testosterone production. Without PCT after a steroid cycle, testosterone recovery can take months. Prolonged or repeated steroid use without adequate PCT can lead to permanent or semi-permanent HPTA impairment.
MK-677: NO suppression. Because it has no androgen receptor activity, MK-677 does not suppress testosterone. No PCT is needed.
Safety Profile Compared — What the Evidence Shows
Peptides generally carry the mildest side effect profile of the three categories, SARMs are marketed as "safer than steroids" but still suppress testosterone and have documented liver toxicity, and anabolic steroids have the most severe side effects but also the most extensive published safety data — creating a paradox where the most dangerous category is the best understood.
Peptides: GH secretagogues produce dose-dependent side effects that are generally mild and transient: water retention, facial flushing, mild headache, and potential insulin sensitivity changes at higher doses. Healing peptides (BPC-157, TB-500) are associated with injection site reactions and mild nausea. FDA-approved peptide drugs such as semaglutide and tirzepatide have extensive Phase III clinical safety data — the GI side effects (nausea, vomiting, diarrhea) are well-characterized. For research peptides without FDA approval, the major safety concern is product quality in the unregulated market, not inherent compound toxicity.
SARMs: marketed as "safer than steroids," which is true but incomplete. SARMs DO suppress testosterone, CAN cause liver toxicity (multiple cases of severe cholestatic jaundice documented in NCBI LiverTox), disrupt lipid profiles, and carry unknown long-term risks because no SARM has completed the clinical development process. A critical quality concern: a 2017 analysis published in JAMA (Van Wagoner et al.) found that only approximately 52% of SARM products contained the compound listed on the label. Roughly 39% contained an unlisted substance, and 9% contained no active compound at all. Contamination with anabolic steroids was detected in some products.
Steroids: the most extensive safety data of any category — decades of clinical use, abuse research, and epidemiological study. The National Institute on Drug Abuse documents the well-characterized side effects: liver damage (particularly with oral steroids such as methyltestosterone and stanozolol), cardiovascular disease (altered cholesterol, cardiomyopathy), HPTA suppression, gynecomastia, acne, accelerated hair loss, prostate enlargement, and psychiatric effects including aggression and mood disturbances. The side effect profile is severe — but it is thoroughly documented.
The paradox: steroids have the WORST safety profile but the BEST safety data. SARMs have fewer side effects than steroids but far less safety documentation. Peptides have the mildest inherent profile but the least clinical evidence for most individual research compounds (with the important exception of FDA-approved peptide drugs, which have extensive trial data).
Legal Status — Where Each Category Stands in 2026
Over 110 peptides have been approved globally as pharmaceutical drugs, zero SARMs have been approved for any indication, and anabolic steroids are Schedule III controlled substances in the United States — three very different legal positions reflecting three very different levels of regulatory scrutiny.
Peptides: complex and compound-specific. FDA-approved peptide drugs (semaglutide, tirzepatide, tesamorelin, bremelanotide) are legal prescription medications. Research peptides sold under Research Use Only (RUO) labels are legal to purchase for laboratory research but not for human therapeutic use. Several popular peptides (BPC-157, TB-500, CJC-1295, Ipamorelin) were placed on the FDA's Category 2 restricted list for compounding in 2023, with approximately 14 of 19 expected to be reclassified to Category 1 in 2026 — which would restore access through licensed compounding pharmacies with a prescription. For the full peptide legal status by country, see the regulatory guide. For the FDA regulatory timeline, see the complete breakdown.
SARMs: not FDA-approved for any indication. Cannot be legally sold as dietary supplements. The FDA has issued warning letters to companies marketing SARMs for human consumption. Classified as "research chemicals" — available for purchase with research-use disclaimers, but operating in a legal grey area similar to RUO peptides. Banned by WADA and all major sports organizations.
Steroids: Schedule III controlled substances under the Controlled Substances Act. Possession without a valid prescription is a federal offense. Several steroids are FDA-approved for specific medical indications (testosterone for hypogonadism, oxandrolone for muscle wasting, nandrolone for certain anemias). Prescription use is legal. Non-prescription possession and distribution are criminal offenses. Banned by WADA and all major sports organizations.
All three categories are on the WADA Prohibited List. Athletes subject to anti-doping testing should assume that virtually any compound discussed in this article is prohibited.
Which Builds More Muscle? An Honest Comparison
Anabolic steroids produce the greatest direct muscle hypertrophy, followed by SARMs, with peptides producing the most gradual and indirect muscle-building effects — but ranking by raw potency alone ignores the safety, sustainability, and testosterone suppression trade-offs that make each category appropriate for different goals and risk tolerances.
Steroids are the most potent. Testosterone and its derivatives directly activate androgen receptors in muscle tissue, stimulating protein synthesis and nitrogen retention at supraphysiological levels. The muscle-building effects are fast, dramatic, and well-documented. The trade-off: systemic hormonal disruption, HPTA shutdown, cardiovascular risk, liver stress, and legal consequences.
SARMs are moderately potent. They activate androgen receptors in muscle and bone with relative selectivity, producing noticeable muscle growth and strength gains — faster and more direct than peptides, but less dramatic than steroids. Users typically report visible changes within 3–4 weeks. The trade-off: testosterone suppression, incomplete selectivity, liver toxicity risk, and a product market where half the products may not contain what the label claims.
Peptides are the most gradual. GH secretagogues (CJC-1295, Ipamorelin) support muscle growth indirectly through elevated GH and IGF-1 — enhancing protein synthesis, recovery, fat metabolism, and sleep quality. Body composition changes typically become visible at 4–8 weeks of consistent use. Healing peptides (BPC-157, TB-500) support injury recovery and training consistency rather than direct hypertrophy. The trade-off: slower results. The advantage: no testosterone suppression, no HPTA shutdown, no PCT, and a side effect profile that allows sustainable long-term use.
Peptigrity covers peptides because they work with the body's signaling systems rather than overriding them. The trade-off is slower results with a fundamentally different risk calculus. For peptide-specific combination protocols that optimize GH release and recovery, see the peptide stacking guide.
How Does Quality Verification Differ Across Categories?
Peptides have the most developed independent quality verification ecosystem of the three categories — HPLC purity and mass spectrometry identity testing are standardized, batch-specific COA documentation is the norm, and platforms like Peptigrity maintain 378 independent lab tests across dozens of vendors — while a 2017 JAMA study found that only approximately 52% of SARM products contained the compound listed on their label.
Peptide quality verification relies on two standardized analytical methods: HPLC (High-Performance Liquid Chromatography) for purity assessment and mass spectrometry for identity confirmation. Research-grade peptide vendors are expected to provide batch-specific Certificates of Analysis (COAs) with these results. Peptigrity's shop reviews and independent lab test data allow buyers to cross-reference vendor claims against third-party verified results. For the complete verification process, see how to verify peptide quality and the guide on purity standards.
SARM quality is significantly less reliable. The Van Wagoner et al. 2017 JAMA analysis tested 44 SARM products purchased online and found: only 52% contained a SARM at all, 39% contained an unlisted substance (including anabolic steroids in some cases), and 9% contained no active compound whatsoever. Independent verification infrastructure for SARMs is far less developed than for peptides — fewer testing services, fewer standardized methods, and fewer independent review platforms.
Pharmaceutical steroid quality is guaranteed for prescription products dispensed by licensed pharmacies — these undergo full regulatory quality assurance. Underground laboratory (UGL) steroids, however, carry the same contamination and purity risks as unregulated SARMs and research peptides. The quality guarantee disappears the moment you leave the regulated pharmaceutical supply chain.
Peptigrity exists because the peptide quality verification ecosystem needs an independent review platform — not a vendor, not a clinic, not an affiliate site. This platform covers peptides specifically because peptides are the category where the infrastructure for independent testing, shop review, and quality comparison is most developed and most needed.
Frequently Asked Questions
Are BPC-157 and TB-500 considered steroids?
No. BPC-157 is a 15-amino-acid peptide derived from a protein found in human gastric juice. TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring 43-amino-acid protein. Neither compound has a steroid chemical structure (no four-ring cholesterol-derived backbone), neither binds to androgen receptors, and neither affects testosterone production. They are peptides — amino acid chains that promote tissue repair through growth factor modulation, nitric oxide signaling, and cell migration — not through androgenic signaling. Calling BPC-157 or TB-500 a "steroid" is chemically and pharmacologically incorrect.
Can you take SARMs and peptides together?
Some users combine SARMs with peptide stacks — for example, adding Ostarine to a CJC-1295/Ipamorelin GH protocol. Because they act on different receptor systems (androgen receptors vs. GHRH/ghrelin receptors), there is no direct pharmacological conflict. However, the SARM will still suppress testosterone while the peptides will not, creating a mixed hormonal environment. The SARM component will still require PCT after discontinuation. No published research has studied these specific combinations. Peptigrity does not cover SARMs — for peptide combination protocols, see the peptide stacking guide.
Do peptides show up on a drug test?
Standard workplace drug tests do not screen for peptides or SARMs — they test for recreational drugs (THC, cocaine, opioids, amphetamines, PCP). Athletic anti-doping tests (WADA, NCAA, professional sports organizations) DO test for peptides, SARMs, and steroids. Most GH secretagogues, BPC-157, TB-500, GLP-1 drugs, and MK-677 are on the WADA Prohibited List. If you are subject to any athletic anti-doping testing, assume all compounds discussed in this article are prohibited both in-competition and out-of-competition.
Is MK-677 a peptide or a SARM?
Neither. MK-677 (Ibutamoren) is a non-peptide, orally active, small-molecule ghrelin receptor agonist classified as a growth hormone secretagogue. It does not have a peptide amino acid structure (not a peptide), does not bind to androgen receptors (not a SARM), and does not have a steroid ring structure (not a steroid). It is grouped with SARMs by vendors for marketing convenience, not pharmacological accuracy. Wikipedia, NCBI LiverTox, PubChem, and the US Department of Defense all classify it as a non-peptide compound. It does not suppress testosterone and does not require PCT.
Which is safest — peptides, SARMs, or steroids?
Peptides generally have the mildest side effect profile because they work with the body's existing signaling pathways rather than overriding hormonal systems. SARMs carry moderate risk — testosterone suppression, documented liver toxicity, widespread product contamination (only ~52% of products contain the listed compound per published JAMA data). Steroids carry the highest inherent risk — systemic hormonal disruption, cardiovascular damage, liver toxicity, and criminal legal consequences for non-prescription possession. However, "safest" also depends on product quality: an impure or misidentified peptide can be more dangerous than a pharmaceutical-grade prescribed steroid. Quality verification is non-negotiable regardless of category.
This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA for human use. SARMs are not FDA-approved for any indication. Anabolic steroids are controlled substances requiring a prescription. Always consult a qualified healthcare provider before using any compound discussed in this article. Peptigrity is an independent peptide review platform and does not sell, endorse, or recommend specific products or vendors.
